| Bryan Burt
Stanford University, USA
Bryan Burt, M.D., FACS is a general thoracic surgeon and thoracic surgical oncologist. He earned his medical degree from Weill Medical College of Cornell University in New York, New York. Dr. Burt continued his training with a residency in general surgery and thoracic surgery at Brigham & Women’s Hospital In Boston, MA. His research efforts are concentrated on determination of the immunologic determinants of pleural mesothelioma and non-small cell lung cancer with a focus on novel therapeutics of these diseases.Dr. Burt is the Associate Chief of Thoracic Surgery at Baylor College of Medicine. He is part of a multidisciplinary team that offers a patient-centered approach to the management of lung cancer, malignant pleural mesothelioma, esophageal cancer, other thoracic malignancies, as well as benign conditions of the lung and esophagus.
National Cancer Center Hospital East, Japan
Memorial Sloan-Kettering Cancer Center, USA
James Huang is a thoracic surgeon who specializes in the minimally invasive treatment of cancers of the chest. His research focuses on outcomes of lung cancer treatment, as well as obtaining a greater understanding of thymoma and other thymic tumors. He also has an interest in surgical education and serves the Program Director of the Thoracic Surgery Fellowship Program. He received his MD degree, and Masters at Columbia University, completed a surgical residency at Brigham and Women’s Hospital/Harvard Medical School, and completed fellowships in Thoracic Surgery at NY-Presbyterian/Weill Cornell, Memorial Sloan Kettering Cancer Center and the University of Pittsburgh Medical School.
| Chang-Hyun Kang
Seoul National University, South Korea
Dr. Chang Hyun Kang is a professor of Seoul National University College of Medicine in the department of Thoracic and Cardiovascular Surgery. He graduated Seoul National University College of Medicine and was trained in Seoul National University Hospital. His major interest includes lung cancer, thymic malignancy, and esophageal cancer. He has authored or co-authored more than 100 madical papers on these issues. He is now focusing on minimally invasive surgery, especially robotic surgery and multi-center clinical studies. He recently published several articles on minimally invasive surgery in lung cancer and thymic tumors. He is actively working on the robotic surgery program in his country, especially in thymic tumors and esophageal cancer. He is a vice president of Korean robotic study group in thoracic and cardiovascular surgery. He is now playing major role in of Korean multicenter database project on thymic malignancy. In this multi-center study group, he established Korean database of thymic malignancy and is going to perform multi-center prospective clinical trial.
Swedish Cancer Institute, USA
Dr.Brian Louie is currently the Director of Thoracic Research and Education and Co-Director of the Minimally Invasive Thoracic Surgery Program in the Division of Thoracic Surgery at Swedish Medical Center and Cancer Institute. He received his MD from the University of Toronto in Canada. He trained in general surgery at the University of Alberta in Edmonton Canada during which he also completed a Master’s in Public Health in health technology evaluation. Following that, he went on to complete general thoracic surgery training at McMaster University in Hamilton Canada. After completing a clinical fellowship in thoracic and esophageal disease under the direction of Dr. Tom DeMeester at the University of Southern California, he joined the Division of Thoracic Surgery at Swedish Cancer Institute and Medical Center.He holds certifications from the Royal College of Surgeons of Canada in general and thoracic surgery and from the American Board of Surgery in general surgery. His main interests are in esophageal cancer, treatment and pathophysiology of GERD, minimally invasive lung and mediastinal surgery particularly using the da Vinci robot, technology and cost evaluation. He has authored 51 published articles and 10 book chapters.
Stanford University, USA
Sukhmani (Suki) Padda is an Instructor of Medicine in the Department of Medicine, Division of Oncology at Stanford University, with a specific interest in immunotherapy/tumor immunology and early phase clinical trials in thoracic oncology. She graduated from a 6-year medical program, Northeastern Ohio Medical University in 2007. The year following medical school, she did clinical research in early phase trials in thoracic malignancies with Dr. Heather Wakelee, Associate Professor of Medicine at Stanford University. She completed internal medicine residency and hematology/oncology fellowship at Stanford University in 2014. She is an active member of the International Thymic Malignancy Interest Group (ITMIG) and has worked on immunology-focused studies in this arena, including examining PD-L1 expression in a thymic malignancy tissue microarray and collaborating with other ITMIG members to understand the effect of paraneoplastic/autoimmune syndromes on clinical outcomes for thymoma patients using the retrospective ITMIG database. She is also working on clinical trials of novel combinations in EGFR mutated and KRAS mutated non-small cell lung cancer patients and a novel class of immunotherapeutics in solid tumor patients.
Radiologist of Shanghai Chest Hospital, China
Specialized in CT and MRI diagnosis of Thoracic disease.
University of Tokushima, Japan
Yousuke Takahama is a Professor of Experimental Immunology, University of Tokushima, Japan. He is on the Board of Japanese Society for Immunology and on the Editorial Board of European Journal of Immunology. He is also a Treasurer of Federation of Immunological Societies of Asia-Oceania and the President of the Japanese Association for Research on the Thymus. He is a founding member of the Global Thymus Network. His main interests are thymus and thymocyte development.
Stanford University, USA
Dr. Heather Wakelee is an Associate Professor of Medicine at Stanford University in the Division of Oncology where she leads the thoracic medical oncology research program and has authored or co-authored over 100 medical articles on thoracic malignancies. She attended Princeton University and then went to medical school at Johns Hopkins University. She returned to her native California for internal medicine residency and fellowship training in medical oncology at Stanford University. Dr. Wakelee’s focus is in clinical research in thoracic malignancies including lung cancer and thymic malignancies. Dr. Wakelee has led multiple investigator-initiated protocols looking at bevacizumab and other anti-angiogenic agents. Additional areas of interest include drugs and drug combinations focused on overcoming EGFR and ALK inhibitor resistance, Met inhibitors and novel immune modulatory agents. Other research focuses on sex differences in lung cancer, lung cancer in never-smokers and evaluation of novel biomarkers including circulating tumor cells and cell-free DNA. She serves on the steering committee and is the chair of the Research Working Group of the International Thymic Malignancies Interest Group (ITMIG) and has written and conducted two phase II trials of novel agents in this rare disease entity. She is very active in the American Society of Clinical Oncology (ASCO) and also the International Association for the Study of Lung Cancer (IASLC).
University of Heidelberg, Germany
Dr. Weis is a resident in the Institute of Pathology at the University Medical Centre Mannheim, University of Heidelberg. His areas of expertise include thymic pathology, general pathology and especially digital image processing of histological data.Dr. Weis focuses his research on thymic epithelial neoplasms and digital pathology. In this context, he became 2013 member of the International Thymic Malignancy Interest Group.Dr. Weis studied medicine at the University of Heidelberg in Germany. After passing his exam, he started his residency in surgical pathology at the Institute of Pathology at the University Medical Centre Mannheim, University of Heidelberg, and began research on thymic malignancies at Prof. Alexander Marx’s work group. In parallel to his medical training, he studied Medical Physics at the University of Heidelberg and graduated with a M.Sc. degree in 2013.
|Jean Claude Zenklusen
Center for Cancer Genomics, USA
Jean Claude Zenklusen was born 1964 in Visp, Switzerland. He earned a Master in Sciences (Biochemistry) from the University of Buenos Aires in 1990. He received his PhD in Cancer Biology & Genetics from The University of Texas, Graduate School of Biomedical Sciences, in 1995. In 1996, he took a post-doctoral position at the National Genome Research Institute where, while participating in the Human Genome Project, he cloned two novel Tumor Suppressor Genes. From 2003 until 2009, he was the Senior Staff Scientist at the Neuro-Oncology Branch of the National Cancer Institute directing the Glioma Molecular Diagnostic Initiative and its companion data portal, Rembrandt. From 2009 until 2013, he served as the Scientific Program Director of the Office of cancer Genomics, where he oversaw a variety of large-scale projects. In August 2013 he was named as Director of The Cancer Genome Atlas, the largest-scale cancer genomics project to date.
Shanghai Chest Hospital, China
Dr. Lei Zhu is a pathologist of Shanghai Chest Hospital, majoring in thoracic pathology.